Experts discuss the integration of GLP-1 receptor agonists in treating neuroendocrine tumors, highlighting safety concerns ...

Effective coordination among multidisciplinary team and individualized management strategies has emerged as a cornerstone of optimal NET care.

Experts discuss the impact of dose escalation in treating neuroendocrine tumors, highlighting recent trials and collaborative research efforts for improved patient outcomes.

As Merck looks for growth opportunities ahead of Keytruda’s tumble over the patent cliff, the company’s future now looks a ...

Merck Announces KEYTRUDA Plus WELIREG Met Primary Endpoint of DFS in Certain Patients With Clear Cell Renal Cell Carcinoma ...

IND application filed for MP0712, the Company’s lead Radio-DARPin candidate targeting DLL3 and co-developed with Orano Med, with Phase 1 initiation expected before year end 2025 First patient images ...

Rare tumors are defined as cancers with an incidence of less than 6 per 100,000 persons per year. Due to their low prevalence ...

Bristol-Myers Squibb Company remains a solid, cash-generative blue-chip stock, with expected slow growth & patience. Learn ...

Colon cancer symptoms in women are similar to those in men, but they can be confused with gynecological issues, like cramping ...

Scientists are exploring leading-edge technologies that could transform how cancer is studied, detected and treated by catching it earlier, when it's more treatable and survival rates are highest.

A research team led by the Medical University of Vienna, the HUN-REN Research Centre for Natural Sciences and the Eötvös Loránd University in Budapest has developed a groundbreaking new ...